Supernus Pharmaceuticals | SUPN - Passivo Circulante





Passivo Circulante Alterar Data
Abbott USD 16.5B 1.91B 2025-12
ANI Pharmaceuticals USD 278.11M 7.56M 2025-12
Aurora Cannabis CAD 145.94M 21.82M 2025-12
Bristol-Myers Squibb USD 28.14B 608M 2025-09
Canopy Growth CAD 98.29M 17.19M 2025-12
Cara Therapeutics USD 10.68M 9.48M 2025-06
Corcept Therapeutics USD 166.08M 6.18M 2025-12
Eisai JPY 387.67B 9.42B 2025-12
Eli Lilly USD 35.23B 4.91B 2025-12
Novo Nordisk DKK 215.66B 18.7B 2025-12
Pacira USD 120.59M 13.51M 2025-12
Perrigo USD 1.01B 132.4M 2025-12
Pfizer USD 36.6B 1.13B 2025-09
Supernus Pharmaceuticals USD 338.17M 7.54M 2025-12
United Therapeutics USD 560.6M 14.3M 2025-12
Xeris Pharmaceuticals USD 109.57M 6.63M 2025-12